

Bibliography

1. Hatano T, Lin CH, Cardoso F. A Biological Framework for Parkinson's Disease: Advances in alpha-Synuclein-Centered Biomarkers and Staging. *J Neurochem*. Jun 2026;170(6):e70491. doi:10.1111/jnc.70491
2. Fernandes Gomes B, Farris CM, Ma Y, et al. alpha-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. *Parkinsonism Relat Disord*. Dec 2023;117:105807. doi:10.1016/j.parkreldis.2023.105807
3. Martinez-Valbuena I, Emamikhah M, Olszewska DA, et al. A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism. *Nat Med*. Jun 2026;32(6):2073–2082. doi:10.1038/s41591-026-04398-3
4. Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification: a cross-sectional study. *Lancet Neurol*. May 2023;22(5):407–417. doi:10.1016/S1474-4422(23)00109-6
5. Pedersen CC, Maple-Groden J, Lange J. A systematic review of biofluid phosphorylated alpha-synuclein in Parkinson's disease. *Parkinsonism Relat Disord*. Mar 2025;132:107240. doi:10.1016/j.parkreldis.2024.107240
6. Trevisan L, Gaudio A, Monfrini E, Avanzino L, Di Fonzo A, Mandich P. Genetics in Parkinson's disease, state-of-the-art and future perspectives. *Br Med Bull*. Mar 13 2024;149(1):60–71. doi:10.1093/bmb/ldad035
7. Schneider SA, Alcalay RN. Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. *Mov Disord*. Nov 2017;32(11):1504–1523. doi:10.1002/mds.27193
8. Milber JM, Noorigian JV, Morley JF, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. *Neurology*. 2012;79(24):2307–2314. doi:10.1212/WNL.0b013e318278fe32
9. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. *Lancet Neurol*. May 2021;20(5):385–397. doi:10.1016/S1474-4422(21)00030-2
10. Suh M, Im JH, Choi H, Kim HJ, Cheon GJ, Jeon B. Unsupervised clustering of dopamine transporter PET imaging discovers heterogeneity of parkinsonism. *Hum Brain Mapp*. Nov 2020;41(16):4744–4752. doi:10.1002/hbm.25155
11. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. Oct 2015;30(12):1591–601. doi:10.1002/mds.26424
12. Willis AW, Roberts E, Beck JC, et al. Incidence of Parkinson disease in North America. *NPJ Parkinsons Dis*. Dec 15 2022;8(1):170. doi:10.1038/s41531-022-00410-y
13. Conn H, Jankovic J. Drug-induced parkinsonism: diagnosis and treatment. *Expert Opin Drug Saf*. Dec 2024;23(12):1503–1513. doi:10.1080/14740338.2024.2418950
14. Coughlin DG, Shifflett B, Farris CM, et al. alpha-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease. *Neurology*. Mar 11 2025;104(5):e210279. doi:10.1212/WNL.0000000000210279
15. Donadio V, Incensi A, Rizzo G, et al. Skin intraneural phosphorylated alpha-synuclein is a highly specific biomarker for early Parkinson's disease. *Brain*. Mar 5 2026;149(3):856–866. doi:10.1093/brain/awaf313
16. Janarthanam C, Orrú CD, Hughson AG, et al. Multisite study: Predicting Lewy body disease using skin biopsy α -synuclein seed amplification assays. *J Neuropathol Exp Neurol*. Jun 1 2026;doi:10.1093/jnen/nlag048

17. Graff-Radford J, Boeve BF, Pedraza O, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. *Brain*. Aug 2012;135(Pt 8):2470–7. doi:10.1093/brain/aws173
18. McKeith IG, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. *British Medical Journal*. 1992;305(673)doi:10.1136/bmj.305.6855.673
19. Palmqvist S, Rossi M, Hall S, et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. *Nat Med*. Aug 2023;29(8):1971–1978. doi:10.1038/s41591-023-02450-0
20. Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. *Nat Med*. Aug 2023;29(8):1964–1970. doi:10.1038/s41591-023-02449-7
21. Rossi M, Baiardi S, Teunissen CE, et al. Diagnostic Value of the CSF alpha-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. *Neurology*. Aug 31 2021;97(9):e930–e940. doi:10.1212/WNL.00000000000012438
22. McKeith IG, Boeve BF, Dickson DW. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88–100. doi:10.1212/WNL.00000000000004058
23. Guerreiro R, Ross OA, Kun-Rodrigues C, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurol*. Jan 2018;17(1):64–74. doi:10.1016/S1474-4422(17)30400-3
24. Wyman-Chick KA, Ferman TJ, Weintraub D, et al. Distinguishing Prodromal Dementia With Lewy Bodies From Prodromal Alzheimer Disease: A Longitudinal Study. *Neurol Clin Pract*. Feb 2025;15(1):e200380. doi:10.1212/CJP.000000000000200380
25. Sekiya H, Matsubara T, DeTure MA, Dickson DW. Neuropathology of Lewy body dementia: Lewy-related pathology, alpha-synuclein oligomers, and comorbid pathologies. *Mol Neurodegener*. Nov 3 2025;20(1):117. doi:10.1186/s13024-025-00900-6
26. Coughlin DG, MacLeod KR, Middleton JS, et al. Association of CSF alpha-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy Bodies. *Neurology*. Aug 13 2024;103(3):e209656. doi:10.1212/WNL.00000000000209656
27. Esteller-Gauxax D, Perez Millan A, Sarto J, et al. alpha-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers. *Neurology*. Oct 7 2025;105(7):e214040. doi:10.1212/WNL.00000000000214040
28. Ma Y, Farris CM, Weber S, et al. Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. *Lancet Neurology*. 2024;23(12):1225–1237. doi:10.1016/S1474-4422(24)00364-7
29. Nandanwar D, Truong DD. Multiple system atrophy: Diagnostic challenges and a proposed diagnostic algorithm. *Clin Park Relat Disord*. 2024;11:100271. doi:10.1016/j.prdoa.2024.100271
30. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. *Mov Disord*. Jun 2022;37(6):1131–1148. doi:10.1002/mds.29005
31. Sailer A, Scholz SW, Nalls MA. A genome-wide association study in multiple system atrophy. *Neurology*. 2016;87(15):1591–1598. doi:10.1212/WNL.0000000000003221
32. Sekiya H, Koga S, Murakami A, et al. Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank. *Neurology*. Dec 12 2023;101(24):e2460–e2471. doi:10.1212/WNL.000000000000207905
33. Goldstein DS, Holmes C, Cannon ROI, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. *New England Journal of Medicine*. 1997;336(10):696–702. doi:10.1056/NEJM199703063361004

34. Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: predictors of conversion to clinical CNS involvement. *Neurology*. 2017;88(12):1129–1136. doi:10.1212/WNL.0000000000003737
35. Coon EA, Mandrekar JN, Berini SE, et al. Predicting phenoconversion in pure autonomic failure. *Neurology*. Aug 18 2020;95(7):e889–e897. doi:10.1212/WNL.0000000000010002
36. Giannoccaro MP, Avoni P, Rizzo G, et al. Presence of Skin alpha-Synuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome. *J Parkinsons Dis*. 2022;12(2):585–591. doi:10.3233/JPD-212904
37. Vaughan DP, Fumi R, Theilmann Jensen M, et al. Evaluation of Cerebrospinal Fluid alpha-Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome. *Mov Disord*. Dec 2024;39(12):2285–2291. doi:10.1002/mds.30019
38. Jabbari E, Holland N, Chelban V, et al. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. *JAMA Neurol*. Mar 1 2020;77(3):377–387. doi:10.1001/jamaneurol.2019.4347
39. Plastini MJ, Abdelnour C, Young CB, et al. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. *Ann Clin Transl Neurol*. May 2024;11(5):1197–1210. doi:10.1002/acn3.52034
40. Tosun D, Hausle Z, Iwaki H, et al. A cross-sectional study of alpha-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function. *Alzheimers Dement*. Aug 2024;20(8):5114–5131. doi:10.1002/alz.13858
41. Twohig D, Nielsen HM. alpha-synuclein in the pathophysiology of Alzheimer's disease. *Mol Neurodegener*. Jun 11 2019;14(1):23. doi:10.1186/s13024-019-0320-x
42. Martinez-Valbuena I, Fullam S, O'Dowd S, Tartaglia MC, Kovacs GG. alpha-Synuclein seed amplification assay positivity beyond synucleinopathies. *EBioMedicine*. Oct 2025;120:105925. doi:10.1016/j.ebiom.2025.105925
43. Arnold MR, Coughlin DG, Brumbach BH, et al. α -Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α -Synuclein in the Context of Co-Pathology and Non-LBD Diagnoses. *Annals of Neurology*. 2022;92(4):650–662. doi:10.1002/ana.26453
44. Fernandes Gomes B, Farris CM, Ma Y, et al. Alzheimer's disease traits in Parkinson's disease without alpha-synuclein seeding. *Alzheimers Dement*. May 2025;21(5):e70284. doi:10.1002/alz.70284
45. Kon T, Tomiyama M, Wakabayashi K. Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. *Neuropathology*. Feb 2020;40(1):30–39. doi:10.1111/neup.12597
46. Goedert M, Jakes R, Spillantini MG. The Synucleinopathies: Twenty Years On. *J Parkinsons Dis*. 2017;7(s1):S51–S69. doi:10.3233/JPD-179005
47. Bras IC, Dominguez-Mejide A, Gerhardt E, et al. Synucleinopathies: Where we are and where we need to go. *J Neurochem*. May 2020;153(4):433–454. doi:10.1111/jnc.14965
48. Sharma M, Burre J. alpha-Synuclein in synaptic function and dysfunction. *Trends Neurosci*. Feb 2023;46(2):153–166. doi:10.1016/j.tins.2022.11.007
49. Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. *Cell Death Dis*. Mar 1 2023;14(3):176. doi:10.1038/s41419-023-05672-9
50. Yaribash S, Mohammadi K, Sani MA. Alpha-Synuclein Pathophysiology in Neurodegenerative Disorders: A Review Focusing on Molecular Mechanisms and Treatment

Advances in Parkinson's Disease. *Cell Mol Neurobiol.* Mar 26 2025;45(1):30. doi:10.1007/s10571-025-01544-2

51. Soto C, Mollenhauer B, Hansson O, et al. Toward a biological definition of neuronal and glial synucleinopathies. *Nat Med.* Feb 2025;31(2):396–408. doi:10.1038/s41591-024-03469-7
52. Marek K, Russell DS, Concha-Marambio L, et al. Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study. *EBioMedicine.* 2025;112doi:10.1016/j.ebiom.2025.105567
53. Middleton JS, Hovren HL, Kha N, et al. Seed amplification assay results illustrate discrepancy in Parkinson's disease clinical diagnostic accuracy and error rates. *J Neurol.* Dec 2023;270(12):5813–5818. doi:10.1007/s00415-023-11810-2
54. Orru CD, Vaughan DP, Vijiaratnam N, et al. Diagnostic and prognostic value of alpha-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. *Lancet Neurol.* Jul 2025;24(7):580–590. doi:10.1016/S1474-4422(25)00157-7
55. Poggiolini I, Gupta V, Lawton M, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. *Brain.* Apr 18 2022;145(2):584–595. doi:10.1093/brain/awab431
56. Russo MJ, Orru CD, Concha-Marambio L, et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease. *Acta Neuropathol Commun.* Nov 6 2021;9(1):179. doi:10.1186/s40478-021-01282-8
57. Samudra N, Fischer DL, Lenio S, et al. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort. *Alzheimers Dement.* May 2024;20(5):3334–3341. doi:10.1002/alz.13799
58. Siderowf A, Concha-Marambio L. High diagnostic accuracy of the α -synuclein seed amplification assay informs Parkinson's disease heterogeneity and disease onset in the PPMI cohort. 2023.
59. Smith R, Hovren H, Bowser R, et al. Misfolded alpha-synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment. *Eur J Neurol.* Apr 2024;31(4):e16206. doi:10.1111/ene.16206
60. Tosun D, Hausle Z, Thropp P, et al. Association of CSF alpha-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study. *Alzheimers Dement.* Dec 2024;20(12):8444–8460. doi:10.1002/alz.14276
61. Weber S, Farris CM, Ma Y, et al. Anosmia and Upper Limb Rigidity-A Potential Phenotype of Idiopathic Normal Pressure Hydrocephalus with Cerebrospinal Fluid alpha-Synuclein Seeds. *Mov Disord.* Jun 2025;40(6):1206–1213. doi:10.1002/mds.30184
62. Shahnawaz M, Mukherjee A, Pritzkow S, et al. Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy. *Nature.* Feb 2020;578(7794):273–277. doi:10.1038/s41586-020-1984-7
63. Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L. alpha-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward. *Neurology.* Aug 2 2022;99(5):195–205. doi:10.1212/WNL.0000000000200878
64. Chahine LM, Chatterjee K, Gochanour C, et al. Dermal Phospho-Alpha-Synuclein Among Individuals With and Without Cerebrospinal Fluid Aggregated Alpha-Synuclein. 2025.
65. Concha-Marambio L, Weber S, Farris CM, et al. Accurate Detection of alpha-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort. *Mov Disord.* Apr 2023;38(4):567–578. doi:10.1002/mds.29329

66. Liu M, Wen T, Luo H, et al. Distinct cutaneous alpha-synuclein signatures in body-first and brain-first Parkinson's disease subtypes. *Brain*. May 5 2026;149(5):1554–1567. doi:10.1093/brain/awaf395
67. Kuzkina A, Panzer C, Seger A, et al. Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy. *Mov Disord*. Jun 2023;38(6):1077–1082. doi:10.1002/mds.29340
68. Haga R, Sugimoto K, Nishijima H, et al. Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy. *Parkinsons Dis*. 2015;2015:167038. doi:10.1155/2015/167038
69. Isaacson J, Freeman R, Gibbons C. Clinical utility of synuclein skin biopsy in the diagnosis and evaluation of synucleinopathies. 2024.
70. Gibbons C, Wang N, Rajan S, et al. Cutaneous alpha-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease. *Neurology*. Apr 11 2023;100(15):e1529–e1539. doi:10.1212/WNL.0000000000206772
71. Gibbons CH, Levine T, Adler C, et al. Skin Biopsy Detection of Phosphorylated alpha-Synuclein in Patients With Synucleinopathies. *JAMA*. Apr 16 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792
72. Miglis MG, Zitser J, Schneider L, et al. Cutaneous alpha-synuclein is correlated with autonomic impairment in isolated rapid eye movement sleep behavior disorder. *Sleep*. Dec 10 2021;44(12)doi:10.1093/sleep/zsab172
73. Rigby MJ, Botha H, Barnard LR, et al. Skin Biopsy for Phosphorylated alpha-Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice. *Mov Disord*. Apr 2026;41(4):962–971. doi:10.1002/mds.70158
74. Bellomo G, Stoops E, Vanbrabant J, et al. Phosphorylated alpha-synuclein in CSF and plasma does not reflect synucleinopathy. *NPJ Parkinsons Dis*. Aug 7 2025;11(1):232. doi:10.1038/s41531-025-01086-w
75. Coughlin DG, Adler CH, Barbosa W, et al. CSF alpha-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge Gaps. *Neurology*. Feb 10 2026;106(3):e214648. doi:10.1212/WNL.0000000000214648
76. Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. *Eur J Nucl Med Mol Imaging*. Jul 2020;47(8):1885–1912. doi:10.1007/s00259-020-04817-8